Mirum (MIRM) Q3 2026 Earnings Call Transcript

Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, up 40% year over year, and raised full-year 2026 guidance to $715 million–$720 million. Management cited growth across its medicines, positive clinical results and Atebrioz’s October launch, while targeting cash-flow-positive status in 2027; cash was $500.5 million at Sept. 30. The company also repurchased $20 million in principal of 2029 convertible notes for $62 million, cutting the outstanding balance by more than 80%, and plans five potential regulatory submissions in the first half of 2027.

Analysis

The key equity question is whether commercial growth can bridge to durable cash generation before pipeline catalysts become the next source of value. The current growth cadence is not equally bankable: adult PFIC expansion depends on finding patients who are largely undiagnosed, while HDV upside likewise requires substantial testing-rate improvement. That makes commercial execution and patient identification—not just clinical efficacy—the limiting variables. Track new patient starts, persistence, and launch/access indicators rather than extrapolating management’s quarterly revenue cadence mechanically.

Near term, the Brelovitug AZURE-4 readout is the principal binary; a merely “supportive” result may be insufficient if investors expect a clean two-trial filing package. A mixed result could pressure the pipeline multiple even if the existing business holds up. VANTAGE in PBC (Q1 2027) and planned first-half 2027 filings extend the catalyst path, but PSC carries added timing/regulatory uncertainty given the older FDA interactions and management’s stated goal of familiarizing the agency with the dataset.

The prospective R&D step-down could materially improve operating leverage, but it is a forecast, not yet a demonstrated earnings inflection. Cash-flow-positive guidance is exposed to launch costs, trial/CMC execution, and the conversion of reported sales into cash; monitor receivables and quarterly operating cash use. Separately, CHOLBAM’s expired orphan exclusivity creates a longer-term generic watch item, although no entrant was reported. Valuation and consensus expectations are not provided, so the growth outlook alone does not establish attractive entry pricing.

Key Decisions for Investors

• Maintain a measured long bias in MIRM rather than buying the guidance raise as a straight-line growth story. Add only if valuation supports the pipeline and commercial franchise; the article provides no price or multiple data to set an entry level.
• Treat AZURE-4 as a near-term risk-control event: reduce exposure or use a defined-risk put spread into the readout if the position is sized for pipeline upside. Reassess on response consistency, safety, and whether the data support the intended two-pivotal-trial BLA package.
• Over the next 1–3 months, verify adult PFIC patient starts and launch traction for Atebrioz, alongside receivables and operating cash flow. Slowing commercial growth or rising cash use would challenge the 2027 cash-flow-positive thesis.
• For 2027, require evidence that R&D falls as guided and filings remain on schedule before capitalizing the projected margin inflection. Any delay to the PSC, PBC, or HDV regulatory path—or credible generic entry into CHOLBAM—would weaken the longer-term thesis.